Get the Stockscreener App
3.45
1.47%
0.05
After Hours:
3.45
Cardiff Oncology Inc stock is traded at $3.45, with a volume of 1.27M.
It is up +1.47% in the last 24 hours and down -35.51% over the past month.
Cardiff Oncology Inc a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical program in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC").
See More
Previous Close:
$3.40
Open:
$3.46
24h Volume:
1.27M
Relative Volume:
0.63
Market Cap:
$229.51M
Revenue:
$488.00K
Net Income/Loss:
$-41.44M
P/E Ratio:
-3.7097
EPS:
-0.93
Net Cash Flow:
$-31.47M
1W Performance:
-4.43%
1M Performance:
-35.51%
6M Performance:
+35.83%
1Y Performance:
+134.69%
1-Day Range:
$3.3752
$3.5075
1-Week Range:
$3.28
$3.64
52-Week Range:
$1.44
$6.42
Cardiff Oncology Inc Stock (CRDF) Company Profile
Name
Cardiff Oncology Inc
Sector
Industry
Phone
858-952-7570
Address
11055 FLINTKOTE AVENUE, SAN DIEGO, CA
Compare CRDF with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRDF
Cardiff Oncology Inc
|
3.45 | 229.51M | 488.00K | -41.44M | -31.47M | -0.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.00 | 108.68B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
681.58 | 74.90B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
640.52 | 38.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.27 | 31.76B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
111.93 | 26.83B | 3.30B | -501.07M | 1.03B | -2.1146 |
Cardiff Oncology Inc Stock (CRDF) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-06-24 | Initiated | Craig Hallum | Buy |
| Jan-05-22 | Initiated | William Blair | Outperform |
| Dec-08-21 | Initiated | Robert W. Baird | Outperform |
| Aug-09-21 | Resumed | Maxim Group | Buy |
| Oct-22-20 | Initiated | H.C. Wainwright | Buy |
| Oct-08-20 | Initiated | Piper Sandler | Overweight |
View All
Cardiff Oncology Inc Stock (CRDF) Latest News
Jane Street Group LLC Cuts Stake in Cardiff Oncology, Inc. (NASDAQ:CRDF) - Defense World
Cardiff Oncology, Inc. (NASDAQ:CRDF) Shares Acquired by Geode Capital Management LLC - Defense World
Barclays PLC Purchases 39,542 Shares of Cardiff Oncology, Inc. (NASDAQ:CRDF) - Defense World
Cardiff Oncology updates bylaws, changes fiscal year - Investing.com India
Cardiff Oncology Inc (NASDAQ: CRDF) Is A Buzzing Hot Stock - Stocks Register
Cardiff Oncology updates bylaws, changes fiscal year By Investing.com - Investing.com South Africa
State Street Corp Purchases 27,628 Shares of Cardiff Oncology, Inc. (NASDAQ:CRDF) - Defense World
Short Interest in Cardiff Oncology, Inc. (NASDAQ:CRDF) Expands By 21.6% - MarketBeat
Institutions along with individual investors who hold considerable shares inCardiff Oncology, Inc. (NASDAQ:CRDF) come under pressure; lose 27% of holdings value - Simply Wall St
While institutions own 25% of Cardiff Oncology, Inc. (NASDAQ:CRDF), retail investors are its largest shareholders with 57% ownership - Yahoo Finance
Cardiff Oncology, Inc. (NASDAQ:CRDF) Shares Bought by Charles Schwab Investment Management Inc. - Defense World
Cardiff Oncology CFO James Levine purchases $36,725 in shares By Investing.com - Investing.com Canada
10 Health Care Stocks With Whale Alerts In Today's Session - Benzinga
Cardiff Oncology, Inc. (NASDAQ:CRDF) Short Interest Update - MarketBeat
Piper Sandler Boosts Cardiff Oncology (NASDAQ:CRDF) Price Target to $10.00 - Defense World
Undercovered Dozen: Ubiquiti, Ready Capital, Cardiff Oncology, Vodafone + - Seeking Alpha
Cardiff Oncology price target raised to $10 from $7 at Piper Sandler - Yahoo Finance
Cardiff Oncology (NASDAQ:CRDF) Stock Price Expected to Rise, Piper Sandler Analyst Says - MarketBeat
Cardiff Oncology director Gary Pace buys $940,199 in stock By Investing.com - Investing.com South Africa
Cardiff Oncology director Gary Pace buys $940,199 in stock - Investing.com
Cardiff Oncology: The Long-Awaited First-Line MCRC Data Are Here, But The Work Is Just Beginning - Seeking Alpha
3 Penny Stocks to Watch Now, 12/12/24 - TipRanks
CRDF Stock Soars on Robust Efficacy Data From Colorectal Cancer Study - MSN
Cardiff Oncology announces positive colorectal data and $40m stock oversubscription - Yahoo Finance
Biotech Stock Roundup: BIOA Down on Study Update, QURE, CRDF Gain on Study Data & More - Yahoo Finance
Cardiff value doubles on first-line colorectal cancer data - The Pharma Letter
Cardiff Oncology Reports Promising Phase 2 Trial Results - Yahoo Finance
Cardiff Oncology (NASDAQ:CRDF) Stock Quotes, Forecast and News Summary - Benzinga
Cardiff Oncology stock soars on oversubscribed $40M underwritten registered direct offering - MSN
Cardiff shares crest on first-line colorectal cancer response data - FirstWord Pharma
Cardiff Oncology: Beats Standard Of Care In First-Line Metastatic Colorectal Cancer - Seeking Alpha
Cardiff Aims To Change Standard Of Care For Some Colorectal Cancers - News & Insights
In midstage colorectal cancer trial, Cardiff's KRAS candidate linked to 64% response rate at higher dose - Fierce Biotech
What's Going On With Cardiff Oncology Stock On Tuesday? - AOL
Cardiff stock soars on onvansertib data, $40M direct offering - MSN
US Small Business Optimism Hits 3-Year High As Election Results 'Signal A Major Shift' - Benzinga
Cardiff Oncology Shares Rise 45% On Initial Positive Results in Colon Cancer Trial - MarketWatch
Cardiff Oncology sets $2.60 price for stock offering - Investing.com India
Cardiff Oncology sets $2.60 price for stock offering By Investing.com - Investing.com Canada
Cardiff Oncology rises on positive results from mid-stage cancer study - XM
Cardiff Oncology Prices Oversubscribed $40 Million Underwritten Registered Direct Offering - GlobeNewswire
Cardiff Oncology Secures $40M in Oversubscribed Offering for Colorectal Cancer Drug Development - StockTitan
Cardiff Oncology, Inc. Announces Positive Initial Data from First-Line RAS-Mutated mCRC Clinical Trial - Marketscreener.com
Cardiff Oncology (CRDF) Announces Positive Initial Data from First-line RAS-mutated mCRC Clinical Trial - StreetInsider.com
Global Kras Inhibitors Market Projected CAGR 4.98% for 2024 - openPR
Cardiff Oncology Announces Positive Initial Data from First-line RAS-mutated mCRC Clinical Trial - GlobeNewswire
Cardiff Oncology's Cancer Drug Shows Stunning 64% Response Rate in Phase 2 Trial - StockTitan
U.S. shares higher at close of trade; Dow Jones Industrial Average up 0.23% - MSN
CRDF (Cardiff Oncology) Momentum Rank : 6 (As of Dec. 05, 2024) - GuruFocus.com
Argentine Peso/Australian Dollar (ARSAUD) QuotePress Release - The Globe and Mail
Cardiff Oncology Inc Stock (CRDF) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.65%
4.62%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):